264 related articles for article (PubMed ID: 28633343)
1. An unknown reaction to pembrolizumab: giant cell arteritis.
Micaily I; Chernoff M
Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
[No Abstract] [Full Text] [Related]
2. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
3. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
[No Abstract] [Full Text] [Related]
4. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
Freitas C; Sampaio L; Fernandes G
J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
[No Abstract] [Full Text] [Related]
5. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
[No Abstract] [Full Text] [Related]
6. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
7. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
9. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
10. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
Kogure Y; Ishii Y; Oki M
J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
[No Abstract] [Full Text] [Related]
11. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
Wang H; Zhang L; Liu W
J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
[No Abstract] [Full Text] [Related]
12. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
De Groot M; Compter A; De Langen AJ; Brandsma D
J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330
[No Abstract] [Full Text] [Related]
13. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
Fattore D; Panariello L; Annunziata MC; Fabbrocini G
Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
[No Abstract] [Full Text] [Related]
14. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
[No Abstract] [Full Text] [Related]
15. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
[No Abstract] [Full Text] [Related]
16. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
19. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
Robinson SD; Lai C; Hotton G; Anand G
Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]